查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863190

人工智慧（AI）在癌症诊断的应用：全球洞察、竞争格局及市场预测（至2032年）

Artificial Intelligence (AI) in Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

人工智慧（AI）在癌症诊断领域的市场摘要

  • 全球癌症诊断领域人工智慧（AI）市场规模预计将强劲且永续成长，从 2024 年的 10.4918 亿美元成长到 2032 年的 24.3432 亿美元。
  • 全球癌症诊断人工智慧（AI）市场在 2025 年至 2032 年的预测期内将以 11.16% 的复合年增长率成长。
  • 随着癌症发生率的上升，人们对早期精准检测的需求日益增长，全球癌症诊断领域的人工智慧（AI）市场正迅速发展。人工智慧与电脑断层扫描、MRI、乳房X光片和病理切片等医学影像的融合日益紧密，提高了诊断准确率，减少了误诊，并实现了个人化治疗。主要市场参与企业透过产品发布、合作和收购等策略性倡议，进一步提升了自身的技术能力和市场覆盖范围。这些因素正在加速人工智慧的应用，改善患者预后，并改变癌症诊断方式。
  • 癌症诊断人工智慧 (AI) 市场的主要企业包括 iCAD, Inc.、ibex-ai、罗氏诊断、Kheiron Medical Technologies Limited、MVision AI Inc.、西门子医疗、GE HealthCare、NVIDIA Corporation、Digital Diagnostics Inc.、IBM Corporation、Azra AI、ConcertAI、PathAI、Median Technologies、Paiger. Analytics。
  • 预计北美将继续在人工智慧（AI）癌症诊断市场保持主导地位。这主要归功于该地区较高的癌症发病率、对先进诊断解决方案日益增长的需求、政府的大力支持以及对人工智慧驱动型医疗技术的巨额投资。此外，众多大型人工智慧开发商和知名医学影像公司的存在也进一步推动了市场扩张。人工智慧与电子健康记录（EHR）、精准医疗和数位病理学的融合，显着提高了全部区域癌症检测和诊断的效率、准确性和速度。
  • 在癌症诊断人工智慧 (AI) 市场的组件细分领域中，预计到 2024 年，软体类别将占据最大的市场份额。

推动人工智慧（AI）在癌症诊断市场成长的因素

  • 癌症发生率上升：全球癌症发生率的不断上升是推动癌症诊断领域人工智慧（AI）市场发展的主要因素。随着新增癌症病例数量的持续增长，医疗系统面临着提供及时准确诊断的巨大压力。这种迫切需求促使医院和诊断中心部署基于人工智慧的解决方案，以期更早发现癌症、改善预后并辅助制定有效的治疗方案。日益加重的疾病负担直接推动了对先进诊断技术的需求，使人工智慧成为现代肿瘤治疗的关键工具。
  • 增强医学影像与人工智慧在癌症诊断中的融合：人工智慧与电脑断层扫描、MRI、乳房X光检查和病理切片等医学显像模式的融合，正在提升癌症诊断的准确性、效率和可靠性。人工智慧演算法能够快速处理和分析大量复杂的影像数据，识别出人类放射科医生可能遗漏的细微异常，从而减少假阳性和假阴性结果。这种能力不仅加快了诊断速度，还有助于制定个人化的治疗方案，最终改善患者预后，并优化医疗机构的临床工作流程。
  • 全球主要市场参与企业策略活动日益增多：主要市场参与企业透过产品发布、併购和合作等策略活动，在塑造人工智慧在癌症诊断市场中的地位方面发挥关键作用。这些倡议使企业能够扩展其技术能力，开发创新的人工智慧驱动型诊断解决方案，并巩固其在全球市场的地位。与研究机构、医院和技术供应商的合作也加速了尖端人工智慧工具的商业化，促进了创新，并加强了人工智慧技术在全球肿瘤治疗领域的应用。

人工智慧（AI）在癌症诊断市场的应用报告

本报告全面概​​述了全球市场，重点阐述了关键趋势、成长要素、挑战和机会。报告按组件、癌症类型、最终用户和地区进行了详细的市场细分。报告深入分析了北美、欧洲和亚太地区等主要市场的竞争格局、法规环境和市场动态，并提供了宝贵的见解。报告详细介绍了主要行业参与企业关键数据，以识别市场潜力、制定战略计划，并在快速增长的人工智慧（AI）癌症诊断市场中把握新的机会。

人工智慧（AI）在癌症诊断中的应用是指利用先进的计算演算法、机器学习和数据驱动模型来分析医疗数据，例如影像、实验室结果和病患病历，以辅助疾病的检测、诊断和预后。透过识别人眼难以发现的模式和异常情况，人工智慧可以提高诊断准确率，加快决策速度，并支援个人化治疗方案的製定，从而改善患者预后并提高临床工作流程的效率。

人工智慧（AI）在癌症诊断领域的市场成长受到多种相互关联的因素所驱动。全球癌症发生率的不断攀升使得早期精准检测成为当务之急，迫使医疗机构采用先进的AI诊断解决方案，以改善预后并辅助制定有效的治疗方案。同时，AI与电脑断层扫描、MRI、乳房X光摄影和病理切片等医学显像模式的日益融合，也提高了诊断的准确性和效率。

人工智慧演算法能够快速分析大量复杂的影像数据，检测出人类放射科医生可能遗漏的细微异常，并减少假阳性和假阴性结果，从而加快诊断速度，并实现个人化治疗策略。此外，主要市场参与企业的产品发布、併购和合作等策略性倡议进一步巩固了市场地位。这些倡议正在拓展技术能力，激发创新，并扩大人工智慧驱动的癌症诊断解决方案的全球覆盖范围。

这些因素正在汇聚，推动人工智慧在肿瘤学领域的快速应用，改善患者预后，优化临床工作流程，并改变全球癌症诊断格局。

受癌症发病率上升和对早期精准检测需求不断增长的推动，人工智慧在癌症诊断市场正经历显着增长。人工智慧与电脑断层扫描、MRI、乳房X光检查和病理切片等医学影像技术的融合，提高了诊断准确率，最大限度地减少了误诊，并实现了个人化治疗方案。主要市场参与企业透过产品发布、合作和收购等策略性倡议，进一步增强了自身的技术实力，并扩大了市场份额。这些因素共同推动了人工智慧的广泛应用，改善了患者的治疗效果，并正在改变全球癌症诊断领域的格局。

癌症仍然是市场成长的主要驱动力。根据DelveInsight分析，预计2025年全球新增癌症病例将达2,150万例，2045年将增加至3,250万例。 2025年全球新增乳癌病例约250万例，预计2045年将增加至335万例。同时，预计2025年新增摄护腺癌病例为155万例，至2050年将增加至285万例。日益增长的全球癌症负担推动了对先进诊断解决方案的需求，而人工智慧在提高早期检测、诊断准确性和治疗效果方面发挥关键作用。传统的诊断方法，例如切片检查和人工解读影像，既耗时又容易出现人为错误。相较之下，人工智慧解决方案能够自动检测，分析来自各种影像模式的大量资料集，并整合基因组和患者数据，从而帮助肿瘤科医师制定个人化的治疗方案。

医学影像与人工智慧的融合正在革新癌症诊断，显着提升诊断的准确性、效率和早期发现率。借助深度学习演算法和电脑视觉技术，人工智慧驱动的影像解决方案能够侦测到人类观察者可能忽略的模式和异常情况。这些技术改进了影像分割、病灶检测和肿瘤分类，从而实现更早、更准确的诊断。先进的人工智慧模型能够以更高的灵敏度和特异性区分良性肿瘤和恶性肿瘤，减少假阳性结果和不必要的切片检查。此外，人工智慧工具还有助于监测肿瘤进展、评估治疗效果和预测疾病復发，使肿瘤科医师能够做出更明智的决策，从而实现个人化的患者照护。

主要市场参与企业的策略性倡议正在进一步加速市场成长。例如，2024年9月，罗氏透过其navify®数位病理企业软体，整合了来自八家新合作伙伴的20多种先进人工智慧演算法，扩展了其数位病理平台。此举将提升癌症研究和诊断能力，使病理学家能够无缝存取尖端人工智慧技术，并加速人工智慧解决方案在临床环境中的应用。

因此，癌症发病率的上升、技术的不断创新以及积极的行业策略预计将在预测期内推动全球癌症诊断人工智慧市场显着增长，从而改变肿瘤治疗并提高全球诊断准确性。

然而，全球人工智慧（AI）市场在癌症诊断领域的成长面临许多挑战，尤其是在机器学习和肿瘤学领域。资料可用性有限且资料品质参差不齐是主要障碍，因为人工智慧系统需要大量高品质的资料集才能有效地训练其演算法。不一致或不完整的医学影像、基因组和临床数据会降低模型准确性并降低诊断可靠性。此外，严格的监管和伦理问题进一步限制了市场扩张。人工智慧驱动的诊断工具必须经过广泛的临床检验，以证明其安全性、准确性和有效性，而跨多个地区应对复杂的法规结构可能会延迟核准和产品上市。包括病人知情同意、资料隐私和公平取得在内的伦理考量，也增加了实施的复杂性。

总体而言，数据品质和可用性的限制，加上严格的监管和伦理要求，限制了人工智慧在癌症诊断方面的潜力，即使该技术不断改进早期检测、提高工作流程效率并支持肿瘤学中的精准医疗倡议。

人工智慧（AI）在癌症诊断领域的市场

癌症诊断人工智慧 (AI) 市场細項分析—按组件、癌症类型、最终用户和地区划分

人工智慧（AI）在癌症诊断的应用

预计到2024年，以美国为首的北美地区将占据全球人工智慧（AI）癌症诊断市场51%的主导地位。北美地区在人工智慧（AI）癌症诊断市场的领先地位可归因于该地区较高的癌症发病率、对先进诊断解决方案日益增长的需求、政府的大力支持以及对人工智慧驱动型医疗技术的巨额投资。此外，该地区众多大型人工智慧开发商和知名医学影像公司的存在也进一步推动了市场扩张。人工智慧与电子健康记录（EHR）、精准医疗和数位病理学的融合，显着提高了全部区域癌症检测和诊断的效率、准确性和速度。

根据DelveInsight（2025）的预测，2025年北美将新增约290万例癌症病例，预计2045年将增加至385万例。乳癌是癌症整体负担的主要组成部分，预计2025年新增病例约32.5万例，2045年将增加至38.5万例。人工智慧驱动的诊断解决方案在乳癌检测中发挥关键作用，它能够以极高的准确率分析乳房X光片、超音波和磁振造影（MRI）影像。这些技术不仅减少了假阳性和假阴性，还提高了诊断的可靠性。先进的机器学习演算法可以识别人类放射科医生可能忽略的细微影像模式，从而实现更早、更准确的诊断。此外，人工智慧还可以将影像数据与基因组和临床资讯整合，以辅助进行全面的风险评估、肿瘤分类和个人化治疗方案的发展。

北美市场因主要产业参与企业的策略性倡议（併购、监管核准和新产品发布）而进一步巩固。这些倡议加速了技术创新，拓展了产品系列，并增强了市场影响力，从而促进了创新人工智慧癌症检测和治疗解决方案的普及应用。例如，2023年10月，飞利浦与影像生物标记专家Quibim合作，推出了一款用于磁振造影（MR）前列腺筛检的人工智慧影像和报告解决方案。此类合作对于提升诊断能力和满足该地区日益增长的医疗需求至关重要。

因此，癌症发病率上升、技术不断创新、法规结构支援以及积极的行业策略预计将在预测期内（即 2025-2032 年）推动北美癌症诊断人工智慧市场的发展。

由于完善的医疗保健体系、强大的研发实力以及鼓励数位化医疗应用的政府政策，欧洲癌症诊断领域的人工智慧（AI）市场正稳步成长。德国、英国、法国和荷兰等国在人工智慧诊断工具的应用方面处于主导，尤其是在影像学、病理学和预测分析领域，这些工具有助于提高癌症早期检出率、提升诊断准确性并支持个人化治疗策略。

医院、学术机构和技术供应商之间的合作倡议正在促进创新，并加速人工智慧解决方案的商业化。包括欧盟医疗设备法规 (MDR) 和医疗保健领域人工智慧指南法规结构，透过确保人工智慧诊断系统的安全性、有效性和互通性，正在塑造市场动态。此外，云端运算、巨量资料分析和远端医疗解决方案的日益整合，使得人工智慧工具能够在临床环境中实现扩充性和高效部署。新兴企业和中型企业正透过小众人工智慧应用和创新平台积极推动市场成长，而现有企业则持续利用其丰富的数据资源和技术专长。

因此，欧洲市场的特点是创新、监管合规和技术成熟度之间的平衡互动，推动了人工智慧在癌症诊断领域的广泛应用，并巩固了欧洲在全球格局中作为主要参与企业的地位。

亚太地区癌症诊断人工智慧（AI）市场正经历快速成长，这主要得益于癌症发病率的上升、医疗费用支出的增加以及全部区域先进数位技术的普及应用。中国、日本、印度和韩国等国家正崛起为人工智慧驱动型诊断解决方案的主要中心，这得益于这些国家对医疗基础设施的大量投资、政府推动人工智慧融合的倡议，以及资料科学和医学影像领域专业人才的不断涌现。

人工智慧在诊断影像、病理学和基因组学领域的应用日益广泛，旨在增强早期检测能力、提高诊断准确性并实现个人化治疗方案。医院、研究机构和技术供应商之间的合作正在加速在地化人工智慧解决方案的开发和应用。同时，Start-Ups正专注于开发经济高效且扩充性的平台，以满足不同地区的医疗保健需求。法规结构也在不断发展，以适应基于人工智慧的医疗技术，监管机构优先考虑临床检验、资料隐私和互通性标准，以促进信任和应用。此外，云端运算、远端医疗和行动诊断工具的整合正在扩大人工智慧驱动的癌症诊断的覆盖范围，尤其是在农村和医疗资源匮乏的地区。

因此，亚太市场的特点是充满活力的创新、不断增长的公共和私营部门投资，以及对以患者为中心的在地化人工智慧解决方案的重视，这使得该地区成为全球癌症诊断人工智慧领域快速增长的贡献者。

以下是引领癌症诊断人工智慧（AI）市场的主要企业，它们共同占据最大的市场份额，并主导产业趋势：

  • iCAD, Inc.
  • ibex-ai
  • Roche Diagnostics
  • Kheiron Medical Technologies Limited
  • MVision AI Inc.
  • Siemens Healthineers AG
  • GE HealthCare
  • NVIDIA Corporation
  • Digital Diagnostics Inc.
  • IBM Corporation
  • Azra AI
  • ConcertAI
  • PathAI
  • Median Technologies
  • Paige AI Inc.
  • Therapixel
  • Flatiron
  • Freenome Holdings Inc.
  • Onc.AI
  • Sonrai Analytics

人工智慧（AI）在癌症诊断领域的市场格局相对集中，由少数主要企业和越来越多推动创新的新兴新Start-Ups公司组成。 IBM Watson Health、Google Health、西门子医疗、GE医疗和飞利浦等老牌公司正凭藉其强大的研发能力、广泛的资料生态系统以及与医疗机构的合作关係，不断巩固其市场地位。

这些公司正积极将人工智慧融入其现有的成像和诊断平台，扩展其以肿瘤学为中心的产品系列，并投资于预测分析和精准医疗解决方案；与此同时，新兴企业和中型公司正透过专门的人工智慧演算法、云端基础的诊断平台和针对特定癌症类型的先进病理解决方案，为市场繁荣做出贡献。

策略联盟、併购和创业融资正成为关键的成长策略，使企业能够增强技术实力并拓展地域版图。此外，对互通性且符合监管要求的AI工具的需求日益增长，促使企业优先考虑获得FDA批准、CE认证和开展临床检验研究，以建立市场信誉。儘管市场由主要参与企业主导，但市场仍然对创新持开放态度，AI驱动的多模态诊断、即时影像解读和生物标记发现等领域的进步为新进入者创造了机会。

因此，竞争格局体现了成熟的全球领导者和敏捷的创新者之间的平衡，两者共同加速了人工智慧技术在癌症诊断中的应用，同时保持了适度集中的市场结构。

人工智慧（AI）在癌症诊断市场的最新发展趋势

  • 2025年8月，Esaote宣布其MyLab™ A50和MyLab™ A70超音波诊断设备获得FDA核准。这两款携带式高性能成像平台先前已在国际市场销售，如今获准在美国上市，这标誌着Esaote在诊断成像领域创新方面迈出了重要一步。
  • 2025 年 8 月，FDA 授予 ArteraAI Prostate De Novo 批准，使其成为第一个能够预测非转移性前列腺癌长期结果的 AI 驱动软体医疗设备。

人工智慧（AI）在癌症诊断领域的市场细分

  • 人工智慧 (AI) 在癌症诊断中的应用趋势（按组件划分）
  • 软体
  • 服务
  • 人工智慧（AI）在癌症诊断的应用趋势
  • 乳癌
  • 肺癌
  • 大肠直肠癌
  • 摄护腺癌
  • 脑和神经系统癌症
  • 其他的
  • 人工智慧（AI）在癌症诊断中的应用趋势（按终端用户划分）
  • 医院
  • 诊断中心
  • 其他的
  • 人工智慧（AI）在癌症诊断中的区域趋势
  • 北美癌症诊断人工智慧（AI）市场
  • 美国癌症诊断领域人工智慧（AI）市场
  • 加拿大癌症诊断人工智慧（AI）市场
  • 墨西哥癌症诊断领域的人工智慧（AI）市场
  • 欧洲癌症诊断人工智慧（AI）市场
  • 英国人工智慧（AI）在癌症诊断领域的市场
  • 德国癌症诊断人工智慧（AI）市场
  • 法国癌症诊断领域的人工智慧（AI）市场
  • 义大利癌症诊断人工智慧（AI）市场
  • 西班牙癌症诊断人工智慧（AI）市场
  • 其他欧洲人工智慧（AI）市场在癌症诊断领域的应用
  • 亚太地区癌症诊断人工智慧（AI）市场
  • 中国人工智慧（AI）在癌症诊断领域的市场
  • 日本癌症诊断领域的人工智慧（AI）市场
  • 印度癌症诊断领域的人工智慧（AI）市场
  • 澳洲癌症诊断人工智慧（AI）市场
  • 韩国癌症诊断领域的人工智慧（AI）市场
  • 亚太地区其他人工智慧（AI）市场在癌症诊断领域的应用
  • 世界其他地区人工智慧（AI）在癌症诊断领域的市场
  • 南美洲癌症诊断人工智慧（AI）市场
  • 中东癌症诊断人工智慧（AI）市场
  • 非洲癌症诊断人工智慧（AI）市场

影响分析：人工智慧的创新与应用：

人工智慧驱动的创新和应用正在改变癌症诊断格局，显着提升疾病检测和管理的准确性、效率和个人化程度。先进的机器学习和深度学习演算法正日益融入磁振造影（MRI）、电脑断层扫描（CT）和正子断层扫描（PET）等影像技术，有助于提高癌症早期检出率、实现影像自动判读并最大限度地减少诊断错误。人工智慧驱动的工具能够分析包括基因组、蛋白质组和组织病理学资讯在内的复杂数据集，从而识别生物标记并预测治疗反应，为精准肿瘤学铺平道路。

自然语言处理 (NLP) 应用正在革新数据管理，它能够从电子健康记录、病理报告和临床笔记中提取有价值的信息，从而支持临床决策并减轻医生的工作量。此外，基于人工智慧的预测分析的引入实现了即时风险评估和患者分层，帮助临床医生更有效地制定治疗方法。云端运算、联邦学习和边缘人工智慧的持续进步，进一步实现了跨机构安全、可扩展的协作模式开发，同时也保障了病患隐私。因此，将人工智慧驱动的创新应用于癌症诊断，不仅能够加快诊断流程、提高预后准确性，还能推动癌症诊疗模式转移。

美国关税对癌症诊断领域人工智慧（AI）市场的影响分析：

美国关税政策可能透过影响成本、供应链和创新週期，对人工智慧（AI）在癌症诊断领域的市场成长和竞争力产生重大影响。对半导体、GPU、诊断成像硬体和检测试剂等进口零件征收关税，会增加开发基于人工智慧的诊断工具的公司的生产和营运成本。这些增加的成本可能会转嫁给医院、实验室，最终转嫁给患者，减缓人工智慧技术在肿瘤学领域的广泛应用。特别是小型Start-Ups企业，在这样的条件下可能难以维持创新，因为不断上涨的硬体和资料处理成本限制了它们高效训练和更新模型的能力。同时，关税可能会鼓励对国内製造业和区域供应链的投资，从而增强长期韧性并降低对进口的依赖。然而，向本地化生产转型需要大量的时间和资金投入，这可能会造成暂时的供应限制。

此外，诊断成本的上升可能会影响报销决策，因为支付方和医疗系统会越来越谨慎地考虑是否要承担昂贵的AI驱动检测费用。为了应对这些挑战，各公司正在探索平衡成本和维持创新的策略，例如扩大云端基础营运、申请研究工具的关税豁免以及建立国际伙伴关係。简而言之，虽然美国关税旨在保护国内产业，但对癌症诊断AI市场的短期影响令人担忧：成本上升和创新放缓。然而，从长远来看，这些关税可能会增强国内技术基础。

目录

第一章 人工智慧（AI）在癌症诊断市场报告概述

  • 调查范围
  • 市场区隔
  • 市场假设

2. 人工智慧（AI）在癌症诊断市场的执行摘要

  • 市场概览

第三章：人工智慧（AI）在癌症诊断市场的关键因素分析

  • 市场驱动因素
    • 癌症发生率上升
    • 加强医疗图像与人工智慧在癌症诊断中的融合
    • 全球主要市场参与企业的策略活动日益增多
  • 市场限制与挑战
    • 数据可用性和品质有限
    • 严格的规章制度和道德考量
  • 市场机会
    • 云端运算和基于人工智慧的软体即服务（SaaS）模式的兴起

第四章 影响分析

  • 人工智慧驱动的创新和应用
  • 美国关税的影响分析

第五章 监理分析

  • 美国
  • 欧洲
  • 日本
  • 中国

6. 人工智慧（AI）在癌症诊断市场的应用：波特五力分析

第七章 人工智慧（AI）在癌症诊断领域的市场评估

  • 按组件
    • 软体
    • 服务
  • 按癌症类型
    • 乳癌
    • 肺癌
    • 大肠直肠癌
    • 摄护腺癌
    • 脑和神经系统癌症
    • 其他的
  • 最终用户
    • 医院
    • 诊断中心
  • 地区
    • 北美洲
    • 欧洲
    • 亚太地区
    • 其他地区

第八章 竞争情势

第九章Start-Ups资金筹措与投资趋势

第十章 癌症诊断市场人工智慧（AI）公司及产品概况

  • iCAD, Inc.
  • ibex-ai
  • Roche Diagnostics
  • Kheiron Medical Technologies Limited
  • MVision AI Inc.
  • Siemens Healthineers AG
  • GE HealthCare
  • NVIDIA Corporation
  • Digital Diagnostics Inc.
  • IBM Corporation
  • Azra AI
  • ConcertAI
  • PathAI
  • Median Technologies
  • Paige AI Inc.
  • Therapixel
  • Flatiron,
  • Freenome Holdings Inc.
  • Onc.AI
  • Sonrai Analytics

第十一章：KOL视角

第十二章计划方法

第十三章：关于 DelveInsight

第十四章 免责声明和联络我们

Product Code: DIMDCL0845

Artificial Intelligence (AI) in Cancer Diagnostics Market Summary

  • The global Artificial Intelligence (AI) in Cancer Diagnostics market is expected to increase from USD 1,049.18 million in 2024 to USD 2,434.32 million by 2032, reflecting strong and sustained growth.
  • The global Artificial Intelligence (AI) in Cancer Diagnostics market is growing at a CAGR of 11.16% during the forecast period from 2025 to 2032.
  • The global Artificial Intelligence (AI) in Cancer Diagnostics market is growing rapidly due to rising cancer incidence, which drives demand for early and accurate detection. Increased integration of AI with medical imaging, including CT scans, MRIs, mammograms, and pathology slides, enhances diagnostic precision, reduces errors, and enables personalized treatment. Strategic initiatives by key market players, such as product launches, collaborations, and acquisitions, are further expanding technological capabilities and market reach. Together, these factors are accelerating AI adoption, improving patient outcomes, and transforming cancer diagnostics.
  • The leading companies operating in the Artificial Intelligence (AI) in Cancer Diagnostics market include iCAD, Inc., ibex-ai, Roche Diagnostics, Kheiron Medical Technologies Limited, MVision AI Inc., Siemens Healthineers AG, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., IBM Corporation, Azra AI, ConcertAI, PathAI, Median Technologies, Paige AI Inc., Therapixel, Flatiron, Freenome Holdings Inc., Onc.AI, Sonrai Analytics, and Others.
  • North America is expected to remain a dominant force in the Artificial Intelligence (AI) in Cancer Diagnostics market. This can be attributed to the region's high cancer prevalence, increasing demand for advanced diagnostic solutions, strong government support, and substantial investments in AI-driven healthcare technologies. The presence of leading AI developers and prominent medical imaging companies further fuels market expansion. The integration of AI with electronic health records (EHRs), precision medicine, and digital pathology is significantly enhancing the efficiency, accuracy, and speed of cancer detection and diagnosis across the region.
  • In the component segment of the Artificial Intelligence (AI) in Cancer Diagnostics market, the software category is estimated to account for the largest market share in 2024.

Factors Contributing to the Growth of Artificial Intelligence (AI) in Cancer Diagnostics Market

  • The Rising Cancer Incidence: The growing incidence of cancer worldwide is a major driver of the Artificial Intelligence (AI) in cancer diagnostics market. As the number of new cancer cases continues to rise, healthcare systems face increasing pressure to provide timely and accurate diagnoses. This urgent need is prompting hospitals and diagnostic centers to adopt AI-based solutions that can detect cancer early, improve prognostic accuracy, and support effective treatment planning. The increasing disease burden directly fuels demand for advanced diagnostic technologies, positioning AI as a critical tool in modern oncology care.
  • Increase integration of AI with medical imaging for cancer diagnostics: The integration of AI with medical imaging modalities such as CT scans, MRIs, mammograms, and pathology slides is enhancing the precision, efficiency, and reliability of cancer diagnostics. AI algorithms can process and analyze large volumes of complex imaging data quickly, identify subtle abnormalities that may be missed by human radiologists, and reduce false positives and negatives. This capability not only accelerates diagnosis but also supports personalized treatment planning, ultimately improving patient outcomes and optimizing clinical workflows across healthcare institutions..
  • Increase in strategic activities among the key market players across the globe: Strategic activities by key market players, including product launches, mergers, acquisitions, and collaborations, are playing a significant role in shaping the AI in cancer diagnostics market. These initiatives enable companies to expand their technological capabilities, develop innovative AI-driven diagnostic solutions, and extend their global market presence. Collaborative efforts with research institutions, hospitals, and technology providers also accelerate the commercialization of cutting-edge AI tools, fostering innovation and strengthening the adoption of AI technologies in oncology care worldwide.

Artificial Intelligence (AI) in Cancer Diagnostics Market Report Segmentation

This Artificial Intelligence (AI) in Cancer Diagnostics market report offers a comprehensive overview of the global Artificial Intelligence (AI) in Cancer Diagnostics market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Component (Software and Services), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Brain & Nervous System Cancers, and Others), End-Users (Hospitals, Diagnostic Centers, and Others), and Geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing Artificial Intelligence (AI) in Cancer Diagnostics market.

Artificial Intelligence (AI) in Cancer Diagnostics refers to the use of advanced computational algorithms, machine learning, and data-driven models to analyze medical data such as imaging, lab results, and patient records to assist in disease detection, diagnosis, and prognosis. By recognizing patterns and anomalies often undetectable to the human eye, AI improves diagnostic accuracy, accelerates decision-making, and supports personalized treatment planning, enhancing patient outcomes and streamlining clinical workflows.

The growth of Artificial Intelligence (AI) in cancer diagnostics market is being driven by multiple interrelated factors. The rising incidence of cancer worldwide is creating an urgent need for early and accurate detection, prompting healthcare providers to adopt advanced AI-powered diagnostic solutions that can improve prognostic accuracy and support effective treatment planning. Simultaneously, the increasing integration of AI with medical imaging modalities, including CT scans, MRIs, mammograms, and pathology slides, is enhancing diagnostic precision and efficiency.

AI algorithms can rapidly analyze large volumes of complex imaging data, detect subtle abnormalities that may be overlooked by human radiologists, and reduce false positives and negatives, thereby accelerating diagnosis and enabling personalized treatment strategies. In addition, strategic activities among key market players, such as product launches, mergers, acquisitions, and collaborations, are further strengthening the market. These initiatives expand technological capabilities, foster innovation, and broaden the global reach of AI-driven cancer diagnostic solutions.

Collectively, these factors are driving the rapid adoption of AI in oncology, improving patient outcomes, optimizing clinical workflows, and transforming the landscape of cancer diagnostics worldwide.

What are the latest Artificial Intelligence (AI) in Cancer Diagnostics Market Dynamics and Trends?

The artificial intelligence in cancer diagnostics market is experiencing substantial growth, driven by the rising incidence of cancer and the increasing demand for early and accurate detection. The integration of AI with medical imaging technologies, including CT scans, MRIs, mammograms, and pathology slides, is enhancing diagnostic precision, minimizing errors, and enabling personalized treatment strategies. Strategic initiatives by leading market players, such as product launches, partnerships, and acquisitions, are further strengthening technological capabilities and expanding market presence. Collectively, these factors are driving widespread adoption of AI, improving patient outcomes, and transforming the landscape of cancer diagnostics globally.

Cancer continues to be a primary driver of market growth. According to DelveInsight analysis, the estimated number of new cancer cases worldwide is expected to reach 21.5 million in 2025, rising to 32.5 million by 2045. Breast cancer accounted for approximately 2.5 million new cases globally in 2025, projected to increase to 3.35 million by 2045, while prostate cancer cases are estimated at 1.55 million in 2025, expected to rise to 2.85 million by 2050. This growing global cancer burden is intensifying the demand for advanced diagnostic solutions, with AI playing a pivotal role in early detection, accuracy, and improving treatment outcomes. Traditional diagnostic methods, such as biopsies and manual interpretation of imaging, are often time-consuming and prone to human error. In contrast, AI-powered solutions automate detection, analyze vast datasets from imaging modalities, and integrate genomic and patient data to support oncologists in developing personalized treatment plans.

The integration of AI with medical imaging is revolutionizing cancer diagnostics by enhancing accuracy, efficiency, and early detection. AI-driven imaging solutions, leveraging deep learning algorithms and computer vision, can detect patterns and anomalies that may be overlooked by human observers. These technologies improve image segmentation, lesion detection, and tumor classification, enabling earlier and more precise diagnoses. Advanced AI models can differentiate between benign and malignant tumors with higher sensitivity and specificity, reducing false positives and unnecessary biopsies. Additionally, AI-powered tools assist in monitoring tumor progression, evaluating treatment responses, and predicting disease recurrence, empowering oncologists to make informed decisions for individualized patient care.

Strategic initiatives by key market players are further accelerating market growth. For instance, in September 2024, Roche expanded its digital pathology platform by integrating over 20 advanced AI algorithms from eight new collaborators through its navify(R) Digital Pathology enterprise software. This initiative enhances cancer research and diagnostic capabilities, providing pathologists with seamless access to cutting-edge AI innovations and strengthening the adoption of AI solutions in clinical practice.

Thus, the combination of rising cancer prevalence, continuous technological innovations, and proactive industry strategies is expected to drive significant growth in the global AI in cancer diagnostics market throughout the forecast period, reshaping oncology care and improving diagnostic precision worldwide.

However, the growth of the global Artificial Intelligence (AI) in cancer diagnostics market, particularly in the machine learning and oncology segments, faces significant challenges. Limited data availability and variable quality pose major obstacles, as AI systems require large, high-quality datasets to train algorithms effectively. Inconsistent or incomplete medical imaging, genomic, and clinical data can compromise model accuracy and reduce diagnostic reliability. Additionally, strict regulatory and ethical concerns further constrain market expansion. AI-driven diagnostic tools must undergo extensive clinical validation to demonstrate safety, accuracy, and efficacy, and navigating complex regulatory frameworks across multiple regions can delay approvals and product launches. Ethical considerations, including patient consent, data privacy, and equitable access, add another layer of complexity to implementation.

Collectively, limited data quality and availability, combined with stringent regulatory and ethical requirements, restrict the full potential of AI in cancer diagnostics, even as these technologies continue to enhance early detection, improve workflow efficiency, and support precision medicine initiatives in oncology.

Artificial Intelligence (AI) in Cancer Diagnostics Market Segment Analysis

Artificial Intelligence (AI) in Cancer Diagnostics Market by Component (Software and Services), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Brain & Nervous System Cancers, and Others), End-Users (Hospitals, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Artificial Intelligence (AI) in Cancer Diagnostics Market Regional Analysis

North America Artificial Intelligence (AI) in Cancer Diagnostics Market Trends

North America, led by the U.S., accounted for a dominant 51% share of the global Artificial Intelligence (AI) in Cancer Diagnostics market in 2024. North America's dominance in the artificial intelligence (AI) in cancer diagnostics market can be attributed to the region's high cancer prevalence, increasing demand for advanced diagnostic solutions, strong government support, and substantial investments in AI-driven healthcare technologies. The presence of leading AI developers and prominent medical imaging companies further fuels market expansion. The integration of AI with electronic health records (EHRs), precision medicine, and digital pathology is significantly enhancing the efficiency, accuracy, and speed of cancer detection and diagnosis across the region.

According to DelveInsight (2025), North America is projected to record approximately 2.9 million new cancer cases in 2025, rising to 3.85 million by 2045. Breast cancer, a major contributor to the overall cancer burden, accounted for around 325,000 new cases in 2025, with numbers expected to increase to 385,000 by 2045. AI-powered diagnostic solutions are playing a critical role in breast cancer detection by analyzing mammograms, ultrasounds, and MRI scans with remarkable precision. These technologies not only reduce false positives and negatives but also enhance diagnostic confidence. Advanced machine learning algorithms can identify subtle imaging patterns that may be overlooked by human radiologists, enabling earlier and more accurate diagnoses. Additionally, AI supports comprehensive risk assessment, tumor classification, and personalized treatment planning by integrating imaging data with genomic and clinical information.

The North American market is further strengthened by strategic initiatives among key industry players, including mergers and acquisitions, regulatory approvals, and new product launches. These activities accelerate technological advancements, expand product portfolios, and reinforce market presence, facilitating the introduction of innovative AI-driven solutions for cancer detection and treatment. For instance, in October 2023, Philips partnered with Quibim, a specialist in imaging biomarkers, to launch AI-powered imaging and reporting solutions for magnetic resonance (MR) prostate screenings. Collaborations of this nature are instrumental in advancing diagnostic capabilities and addressing the region's growing healthcare demands.

Thus, the combination of rising cancer incidence, continuous technological innovation, supportive regulatory frameworks, and proactive industry strategies is expected to propel the AI in cancer diagnostics market in North America throughout the forecast period from 2025 to 2032.

Europe Artificial Intelligence (AI) in Cancer Diagnostics Market Trends

The Europe artificial intelligence (AI) in cancer diagnostics market is experiencing steady growth, supported by well-established healthcare systems, strong research and development capabilities, and favorable government policies promoting digital health adoption. Countries such as Germany, the United Kingdom, France, and the Netherlands are leading the adoption of AI-powered diagnostic tools, particularly in imaging, pathology, and predictive analytics, to enhance early cancer detection, improve diagnostic accuracy, and support personalized treatment strategies.

Collaborative initiatives between hospitals, academic institutions, and technology providers are fostering innovation and accelerating the commercialization of AI solutions. Regulatory frameworks, including the European Union's Medical Device Regulation (MDR) and guidelines on AI in healthcare, are shaping market dynamics by ensuring safety, efficacy, and interoperability of AI-based diagnostic systems. Additionally, the growing integration of cloud computing, big data analytics, and telehealth solutions is enabling scalable and efficient deployment of AI tools across clinical settings. Startups and mid-sized companies are actively contributing to market growth through niche AI applications and innovative platforms, while established players continue to leverage their extensive data resources and technological expertise.

Hence, the European market is marked by a balanced interplay between innovation, regulatory compliance, and technological sophistication, driving the widespread adoption of AI in cancer diagnostics and reinforcing Europe's position as a key player in the global landscape.

Asia-Pacific Artificial Intelligence (AI) in Cancer Diagnostics Market Trends

The Asia-Pacific artificial intelligence (AI) in cancer diagnostics market is witnessing rapid growth, driven by rising cancer prevalence, increasing healthcare expenditure, and the adoption of advanced digital technologies across the region. Countries such as China, Japan, India, and South Korea are emerging as key hubs for AI-driven diagnostic solutions due to significant investments in healthcare infrastructure, government initiatives promoting AI integration, and a growing pool of skilled professionals in data science and medical imaging.

AI applications in imaging, pathology, and genomics are being increasingly utilized to enhance early detection, improve diagnostic accuracy, and enable personalized treatment planning. Collaborations between hospitals, research institutions, and technology providers are accelerating the development and deployment of locally relevant AI solutions, while startups are focusing on cost-effective, scalable platforms to address the diverse healthcare needs of the region. Regulatory frameworks are evolving to accommodate AI-based medical technologies, with authorities emphasizing clinical validation, data privacy, and interoperability standards, thereby fostering greater trust and adoption. Moreover, the integration of cloud computing, telemedicine, and mobile diagnostic tools is expanding access to AI-enabled cancer diagnostics, particularly in rural and underserved areas.

Therefore, the Asia-Pacific market is characterized by dynamic innovation, increasing public and private sector investment, and a strong focus on localized, patient-centric AI solutions, positioning the region as a rapidly growing contributor to the global AI in cancer diagnostics landscape.

Who are the major players in the Artificial Intelligence (AI) in Cancer Diagnostics Market?

The following are the leading companies in the Artificial Intelligence (AI) in Cancer Diagnostics market. These companies collectively hold the largest market share and dictate industry trends.

  • iCAD, Inc.
  • ibex-ai
  • Roche Diagnostics
  • Kheiron Medical Technologies Limited
  • MVision AI Inc.
  • Siemens Healthineers AG
  • GE HealthCare
  • NVIDIA Corporation
  • Digital Diagnostics Inc.
  • IBM Corporation
  • Azra AI
  • ConcertAI
  • PathAI
  • Median Technologies
  • Paige AI Inc.
  • Therapixel
  • Flatiron
  • Freenome Holdings Inc.
  • Onc.AI
  • Sonrai Analytics

How is the competitive landscape shaping the Artificial Intelligence (AI) in Cancer Diagnostics market?

The competitive landscape of the artificial intelligence (AI) in cancer diagnostics market is moderately concentrated, characterized by the presence of a few dominant players alongside a growing number of emerging startups driving innovation. Established companies such as IBM Watson Health, Google Health, Siemens Healthineers, GE HealthCare, and Philips are leveraging their strong R&D capabilities, extensive data ecosystems, and partnerships with healthcare institutions to strengthen their market positions.

These firms are actively integrating AI into existing imaging and diagnostic platforms, expanding their oncology-focused product portfolios, and investing in predictive analytics and precision medicine solutions. Meanwhile, startups and mid-sized firms are contributing to market dynamism through specialized AI algorithms, cloud-based diagnostic platforms, and advanced pathology solutions targeting niche cancer types.

Strategic collaborations, mergers and acquisitions, and venture funding are becoming key growth strategies, enabling players to enhance their technological depth and expand geographically. Furthermore, the rising demand for interoperable and regulatory-compliant AI tools has prompted companies to prioritize FDA clearances, CE markings, and clinical validation studies to build market credibility. Despite the dominance of major players, the market remains open to innovation, with AI-driven advancements in multi-modal diagnostics, real-time image interpretation, and biomarker discovery creating opportunities for new entrants.

Hence, the competitive landscape reflects a balance between established global leaders and agile innovators, collectively accelerating the adoption of AI technologies in cancer diagnostics while maintaining a moderately concentrated market structure.

Recent Developmental Activities in Artificial Intelligence (AI) in Cancer Diagnostics Market

  • In August 2025, Esaote announced FDA approval of its MyLab(TM) A50 and MyLab(TM) A70 ultrasound systems. Previously unveiled internationally, these portable, high-performance imaging platforms are now cleared for U.S. distribution, marking a key milestone in Esaote's commitment to innovation in diagnostic imaging.
  • In August 2025, the FDA granted De Novo authorization to ArteraAI Prostate, making it the first AI-powered Software as a Medical Device for prognosticating long-term outcomes in non-metastatic prostate cancer.

Artificial Intelligence (AI) in Cancer Diagnostics Market Segmentation

  • Artificial Intelligence (AI) in Cancer Diagnostics by Component Exposure
  • Software
  • Services
  • Artificial Intelligence (AI) in Cancer Diagnostics Application Exposure
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Brain & Nervous System Cancers
  • Others
  • Artificial Intelligence (AI) in Cancer Diagnostics End-Users Exposure
  • Hospitals
  • Diagnostic Centre
  • Others
  • Artificial Intelligence (AI) in Cancer Diagnostics Geography Exposure
  • North America Artificial Intelligence (AI) in Cancer Diagnostics Market
  • United States Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Canada Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Mexico Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Europe Artificial Intelligence (AI) in Cancer Diagnostics Market
  • United Kingdom Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Germany Artificial Intelligence (AI) in Cancer Diagnostics Market
  • France Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Italy Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Spain Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Rest of Europe Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Asia-Pacific Artificial Intelligence (AI) in Cancer Diagnostics Market
  • China Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Japan Artificial Intelligence (AI) in Cancer Diagnostics Market
  • India Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Australia Artificial Intelligence (AI) in Cancer Diagnostics Market
  • South Korea Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Rest of Asia-Pacific Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Rest of the World Artificial Intelligence (AI) in Cancer Diagnostics Market
  • South America Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Middle East Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Africa Artificial Intelligence (AI) in Cancer Diagnostics Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations and applications are transforming the landscape of cancer diagnostics by enhancing accuracy, efficiency, and personalization in disease detection and management. Advanced machine learning and deep learning algorithms are increasingly being integrated into imaging modalities such as MRI, CT, and PET scans to improve early cancer detection, automate image interpretation, and minimize diagnostic errors. AI-driven tools can analyze complex datasets, including genomic, proteomic, and histopathological information, to identify biomarkers and predict treatment responses, paving the way for precision oncology.

Natural language processing (NLP) applications are also revolutionizing data management by extracting valuable insights from electronic health records, pathology reports, and clinical notes, thereby supporting clinical decision-making and reducing physician workload. Moreover, the adoption of AI-based predictive analytics enables real-time risk assessment and patient stratification, helping clinicians tailor therapies more effectively. Continuous advancements in cloud computing, federated learning, and edge AI are further enabling secure, scalable, and collaborative model development across institutions without compromising patient privacy. Therefore, the integration of AI-powered innovations in cancer diagnostics is not only accelerating diagnostic workflows and improving prognostic accuracy but also driving a paradigm shift toward data-driven, patient-centric oncology care.

U.S. Tariff Impact Analysis on the Artificial Intelligence (AI) in Cancer Diagnostics Market:

U.S. tariff policies can significantly influence the growth and competitiveness of artificial intelligence (AI) in cancer diagnostics market by affecting costs, supply chains, and innovation cycles. Tariffs imposed on imported components such as semiconductors, GPUs, imaging hardware, or laboratory reagents increase production and operational expenses for companies developing AI-based diagnostic tools. This escalation in costs often leads to higher prices for hospitals, laboratories, and ultimately patients, potentially slowing the adoption of AI technologies in oncology. Smaller startups may find it especially difficult to sustain innovation under these conditions, as rising hardware and data processing costs can limit their ability to train and update models efficiently. On the other hand, tariff measures may encourage domestic manufacturing and investment in local supply chains, enhancing long-term resilience and reducing reliance on imports. However, transitioning to local production requires substantial time and capital investment, which may cause temporary supply constraints.

Additionally, higher diagnostic costs may influence reimbursement decisions, as payers and healthcare systems become more cautious about covering expensive AI-driven tests. To mitigate these challenges, companies are exploring strategies such as expanding cloud-based operations, seeking tariff exemptions for research tools, or forming international partnerships to balance costs and maintain innovation momentum. In essence, while U.S. tariffs aim to protect domestic industries, their short-term impact on the AI in cancer diagnostics market may include higher costs and slower innovation, even as they potentially strengthen domestic technological capacity over the long term.

How This Analysis Helps Clients

  • Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
  • Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
  • Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
  • Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the Artificial Intelligence (AI) in Cancer Diagnostics market report study

  • Market size analysis for the current Artificial Intelligence (AI) in Cancer Diagnostics market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the Artificial Intelligence (AI) in Cancer Diagnostics market.
  • Various opportunities available for the other competitors in the Artificial Intelligence (AI) in Cancer Diagnostics market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the Artificial Intelligence (AI) in Cancer Diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Artificial Intelligence (AI) in Cancer Diagnostics market growth in the future?

Frequently Asked Questions for Artificial Intelligence (AI) in Cancer Diagnostics Market

1. What is the growth rate of Artificial Intelligence (AI) in Cancer Diagnostics market?

  • The Artificial Intelligence (AI) in Cancer Diagnostics market is estimated to grow at a CAGR of 11.16% during the forecast period from 2025 to 2032.

2. What is the market for Artificial Intelligence (AI) in Cancer Diagnostics?

  • The Artificial Intelligence (AI) in Cancer Diagnostics market was valued at USD 1,049.18 million in 2024, and is expected to reach USD 2,434.32 million by 2032.

3. Which region has the highest share in the Artificial Intelligence (AI) in Cancer Diagnostics market?

  • North America is expected to remain a dominant force in the Artificial Intelligence (AI) in Cancer Diagnostics market. This can be attributed to the region's high cancer prevalence, increasing demand for advanced diagnostic solutions, strong government support, and substantial investments in AI-driven healthcare technologies. The presence of leading AI developers and prominent medical imaging companies further fuels market expansion. The integration of AI with electronic health records (EHRs), precision medicine, and digital pathology is significantly enhancing the efficiency, accuracy, and speed of cancer detection and diagnosis across the region.

4. What are the drivers for Artificial Intelligence (AI) in Cancer Diagnostics market?

  • The global Artificial Intelligence (AI) in Cancer Diagnostics market is growing rapidly due to rising cancer incidence, which drives demand for early and accurate detection. Increased integration of AI with medical imaging, including CT scans, MRIs, mammograms, and pathology slides, enhances diagnostic precision, reduces errors, and enables personalized treatment. Strategic initiatives by key market players, such as product launches, collaborations, and acquisitions, are further expanding technological capabilities and market reach. Together, these factors are accelerating AI adoption, improving patient outcomes, and transforming cancer diagnostics.

5. Who are the key players operating in the Artificial Intelligence (AI) in Cancer Diagnostics market?

  • Some of the key market players operating in the Artificial Intelligence (AI) in Cancer Diagnostics market include iCAD, Inc., ibex-ai, Roche Diagnostics, Kheiron Medical Technologies Limited, MVision AI Inc., Siemens Healthineers AG, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., IBM Corporation, Azra AI, ConcertAI, PathAI, Median Technologies, Paige AI Inc., Therapixel, Flatiron, Freenome Holdings Inc., Onc.AI, Sonrai Analytics, and Others.

Table of Contents

1. Artificial Intelligence (AI) in Cancer Diagnostics Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Artificial Intelligence (AI) in Cancer Diagnostics Market Executive Summary

  • 2.1 Market at Glance

3. Artificial Intelligence (AI) in Cancer Diagnostics Market Key Factors Analysis

  • 3.1 Artificial Intelligence (AI) in Cancer Diagnostics Market Drivers
    • 3.1.1 The rising cancer incidence
    • 3.1.2 Increase the integration of AI with medical imaging for cancer diagnostics
    • 3.1.3 Increase in strategic activities among the key market players across the globe
  • 3.2 Artificial Intelligence (AI) in Cancer Diagnostics Market Restraints and Challenges
    • 3.2.1 Limited data availability and quality
    • 3.2.2 Strict regulatory and ethical concerns
  • 3.3 Artificial Intelligence (AI) in Cancer Diagnostics Market Opportunity
    • 3.3.1 The rise of cloud computing and AI-based SaaS (Software as a Service) models

4. Impact Analysis

  • 4.1 AI-Powered Innovations and Applications
  • 4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

  • 5.1 The United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Artificial Intelligence (AI) in Cancer Diagnostics Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Artificial Intelligence (AI) in Cancer Diagnostics Market Assessment

  • 7.1 By Component
    • 7.1.1 Software
    • 7.1.2 Services
  • 7.2 By Cancer Type
    • 7.2.1 Breast Cancer
    • 7.2.2 Lung Cancer
    • 7.2.3 Colorectal Cancer
    • 7.2.4 Prostate Cancer
    • 7.2.5 Brain & Nervous System Cancers
    • 7.2.6 Others
  • 7.3 By End-Users
    • 7.3.1 Hospitals
    • 7.3.2 Diagnostic Centre
    • 7.3.3 Others
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.1.2 Canada Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.1.3 Mexico Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
    • 7.4.2 Europe
      • 7.4.2.1 France Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.2 Germany Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.3 United Kingdom Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.4 Italy Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.5 Spain Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.6 Rest of Europe Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.2 Japan Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.3 India Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.4 Australia Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.5 South Korea Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.6 Rest of Asia-Pacific Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
    • 7.4.4 Rest of the World (RoW)
      • 7.4.4.1 Middle East Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.4.2 Africa Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.4.3 South America Artificial Intelligence (AI) in Cancer Diagnostics Market Size In USD Million (2022-2032)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Artificial Intelligence (AI) in Cancer Diagnostics Market Company and Product Profiles

  • 10.1 iCAD, Inc.
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Product Listing
    • 10.1.5 Entropy
  • 10.2 ibex-ai
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Listing
    • 10.2.5 Entropy
  • 10.3 Roche Diagnostics
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Listing
    • 10.3.5 Entropy
  • 10.4 Kheiron Medical Technologies Limited
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Listing
    • 10.4.5 Entropy
  • 10.5 MVision AI Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Listing
    • 10.5.5 Entropy
  • 10.6 Siemens Healthineers AG
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Listing
    • 10.6.5 Entropy
  • 10.7 GE HealthCare
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Listing
    • 10.7.5 Entropy
  • 10.8 NVIDIA Corporation
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Listing
    • 10.8.5 Entropy
  • 10.9 Digital Diagnostics Inc.
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Listing
    • 10.9.5 Entropy
  • 10.10 IBM Corporation
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Listing
    • 10.10.5 Entropy
  • 10.11 Azra AI
    • 10.11.1 Company Overview
    • 10.11.2 Company Snapshot
    • 10.11.3 Financial Overview
    • 10.11.4 Product Listing
    • 10.11.5 Entropy
  • 10.12 ConcertAI
    • 10.12.1 Company Overview
    • 10.12.2 Company Snapshot
    • 10.12.3 Financial Overview
    • 10.12.4 Product Listing
    • 10.12.5 Entropy
  • 10.13 PathAI
    • 10.13.1 Company Overview
    • 10.13.2 Company Snapshot
    • 10.13.3 Financial Overview
    • 10.13.4 Product Listing
    • 10.13.5 Entropy
  • 10.14 Median Technologies
    • 10.14.1 Company Overview
    • 10.14.2 Company Snapshot
    • 10.14.3 Financial Overview
    • 10.14.4 Product Listing
    • 10.14.5 Entropy
  • 10.15 Paige AI Inc.
    • 10.15.1 Company Overview
    • 10.15.2 Company Snapshot
    • 10.15.3 Financial Overview
    • 10.15.4 Product Listing
    • 10.15.5 Entropy
  • 10.16 Therapixel
    • 10.16.1 Company Overview
    • 10.16.2 Company Snapshot
    • 10.16.3 Financial Overview
    • 10.16.4 Product Listing
    • 10.16.5 Entropy
  • 10.17 Flatiron,
    • 10.17.1 Company Overview
    • 10.17.2 Company Snapshot
    • 10.17.3 Financial Overview
    • 10.17.4 Product Listing
    • 10.17.5 Entropy
  • 10.18 Freenome Holdings Inc.
    • 10.18.1 Company Overview
    • 10.18.2 Company Snapshot
    • 10.18.3 Financial Overview
    • 10.18.4 Product Listing
    • 10.18.5 Entropy
  • 10.19 Onc.AI
    • 10.19.1 Company Overview
    • 10.19.2 Company Snapshot
    • 10.19.3 Financial Overview
    • 10.19.4 Product Listing
    • 10.19.5 Entropy
  • 10.20 Sonrai Analytics
    • 10.20.1 Company Overview
    • 10.20.2 Company Snapshot
    • 10.20.3 Financial Overview
    • 10.20.4 Product Listing
    • 10.20.5 Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us

List of Tables

  • Table 1: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global (2022-2032)
  • Table 2: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by Component (2022-2032)
  • Table 3: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by Cancer Type (2022-2032)
  • Table 4: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by End-Users (2022-2032)
  • Table 5: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by Geography (2022-2032)
  • Table 6: Artificial Intelligence (AI) in Cancer Diagnostics Market in North America (2022-2032)
  • Table 7: Artificial Intelligence (AI) in Cancer Diagnostics Market in the United States (2022-2032)
  • Table 8: Artificial Intelligence (AI) in Cancer Diagnostics Market in Canada (2022-2032)
  • Table 9: Artificial Intelligence (AI) in Cancer Diagnostics Market in Mexico (2022-2032)
  • Table 10: Artificial Intelligence (AI) in Cancer Diagnostics Market in Europe (2022-2032)
  • Table 11: Artificial Intelligence (AI) in Cancer Diagnostics Market in France (2022-2032)
  • Table 12: Artificial Intelligence (AI) in Cancer Diagnostics Market in Germany (2022-2032)
  • Table 13: Artificial Intelligence (AI) in Cancer Diagnostics Market in United Kingdom (2022-2032)
  • Table 14: Artificial Intelligence (AI) in Cancer Diagnostics Market in Italy (2022-2032)
  • Table 15: Artificial Intelligence (AI) in Cancer Diagnostics Market in Spain (2022-2032)
  • Table 16: Artificial Intelligence (AI) in Cancer Diagnostics Market in the Rest of Europe (2022-2032)
  • Table 17: Artificial Intelligence (AI) in Cancer Diagnostics Market in Asia-Pacific (2022-2032)
  • Table 18: Artificial Intelligence (AI) in Cancer Diagnostics Market in China (2022-2032)
  • Table 19: Artificial Intelligence (AI) in Cancer Diagnostics Market in Japan (2022-2032)
  • Table 20: Artificial Intelligence (AI) in Cancer Diagnostics Market in India (2022-2032)
  • Table 21: Artificial Intelligence (AI) in Cancer Diagnostics Market in Australia (2022-2032)
  • Table 22: Artificial Intelligence (AI) in Cancer Diagnostics Market in South Korea (2022-2032)
  • Table 23: Artificial Intelligence (AI) in Cancer Diagnostics Market in Rest of Asia-Pacific (2022-2032)
  • Table 24: Artificial Intelligence (AI) in Cancer Diagnostics Market in the Rest of the World (2022-2032)
  • Table 25: Artificial Intelligence (AI) in Cancer Diagnostics Market in the Middle East (2022-2032)
  • Table 26: Artificial Intelligence (AI) in Cancer Diagnostics Market in Africa (2022-2032)
  • Table 27: Artificial Intelligence (AI) in Cancer Diagnostics Market in South America (2022-2032)
  • Table 28: Competitive Landscape
  • Table 29: Startup Funding & Investment Trends

List of Figures

  • Table 1: Artificial Intelligence (AI) in Cancer Diagnostics Market Drivers
  • Table 2: Artificial Intelligence (AI) in Cancer Diagnostics Market Restraints
  • Table 3: Artificial Intelligence (AI) in Cancer Diagnostics Market Opportunities
  • Table 4: AI-Powered Innovations in Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Table 5: US Tariff Impact on Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Table 6: Regulatory Analysis (US, EU, Japan, China)
  • Table 7: Porter's Five Forces Analysis
  • Table 8: Competitive Analysis
  • Table 9: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global (2022-2032)
  • Table 10: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by Component (2022-2032)
  • Table 11: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by Cancer Type (2022-2032)
  • Table 12: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by End-Users (2022-2032)
  • Table 13: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by Geography (2022-2032)
  • Table 14: Artificial Intelligence (AI) in Cancer Diagnostics Market in North America (2022-2032)
  • Table 15: Artificial Intelligence (AI) in Cancer Diagnostics Market in the United States (2022-2032)
  • Table 16: Artificial Intelligence (AI) in Cancer Diagnostics Market in Canada (2022-2032)
  • Table 17: Artificial Intelligence (AI) in Cancer Diagnostics Market in Mexico (2022-2032)
  • Table 18: Artificial Intelligence (AI) in Cancer Diagnostics Market in Europe (2022-2032)
  • Table 19: Artificial Intelligence (AI) in Cancer Diagnostics Market in France (2022-2032)
  • Table 20: Artificial Intelligence (AI) in Cancer Diagnostics Market in Germany (2022-2032)
  • Table 21: Artificial Intelligence (AI) in Cancer Diagnostics Market in United Kingdom (2022-2032)
  • Table 22: Artificial Intelligence (AI) in Cancer Diagnostics Market in Italy (2022-2032)
  • Table 23: Artificial Intelligence (AI) in Cancer Diagnostics Market in Spain (2022-2032)
  • Table 24: Artificial Intelligence (AI) in Cancer Diagnostics Market in the Rest of Europe (2022-2032)
  • Table 25: Artificial Intelligence (AI) in Cancer Diagnostics Market in Asia-Pacific (2022-2032)
  • Table 26: Artificial Intelligence (AI) in Cancer Diagnostics Market in China (2022-2032)
  • Table 27: Artificial Intelligence (AI) in Cancer Diagnostics Market in Japan (2022-2032)
  • Table 28: Artificial Intelligence (AI) in Cancer Diagnostics Market in India (2022-2032)
  • Table 29: Artificial Intelligence (AI) in Cancer Diagnostics Market in Australia (2022-2032)
  • Table 30: Artificial Intelligence (AI) in Cancer Diagnostics Market in South Korea (2022-2032)
  • Table 31: Artificial Intelligence (AI) in Cancer Diagnostics Market in Rest of Asia-Pacific (2022-2032)
  • Table 32: Artificial Intelligence (AI) in Cancer Diagnostics Market in the Rest of the World (2022-2032)
  • Table 33: Artificial Intelligence (AI) in Cancer Diagnostics Market in the Middle East (2022-2032)
  • Table 34: Artificial Intelligence (AI) in Cancer Diagnostics Market in Africa (2022-2032)
  • Table 35: Artificial Intelligence (AI) in Cancer Diagnostics Market in South America (2022-2032)
  • Table 36: Competitive Landscape
  • Table 37: Startup Funding & Investment Trends